Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1244]

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast...

Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )

Optimal timing of radiotherapy following radical prostatectomy

Prof Chris Parker - The Royal Marsden Hospital, London, UK

Optimal timing of radiotherapy following radical prostatectomy ( Prof Chris Parker - The Royal Marsden Hospital, London, UK )

ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma

Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City...

ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma ( Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA )

Latest developments in metastatic prostate cancer from ESMO 2019

Prof Nick James and Prof Nicholas Mottet

Latest developments in metastatic prostate cancer from ESMO 2019 ( Prof Nick James and Prof Nicholas Mottet )

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma

Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City...

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma ( Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA )

Comment: Targeted therapy ivosidenib in cholangiocarcinoma

Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK

Comment: Targeted therapy ivosidenib in cholangiocarcinoma ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019

Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )

ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous...

Prof Byoung Chul Cho - Yonsei University, Seoul, South Korea

ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma ( Prof Byoung Chul Cho - Yonsei University, Seoul, South Korea )

Ovarian highlights from ESMO 2019

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

Ovarian highlights from ESMO 2019 ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )

Real-world use of carfilzomib in relapsed multiple myeloma patients with pre...

Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium

Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-existing cardiovascular comorbidities ( Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium )

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk...

Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands )

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

More from ecancer